Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines: Basel Saturday, October 26, 2024, 14:00 Hrs [IST] This month, the NCCN ...

UK biotech Astex has hailed the US approval and launch of Novartis’ latest breast cancer drug, ribociclib – which the Cambridge-based firm helped to discover and develop. Formed in 1999 and ...

Novartis. “Importantly, the NCCN Guideline recommendation of ribociclib in this broad population reaffirms the importance of offering eligible patients with early breast cancer, including those ...

Astex, which is a wholly-owned subsidiary of Japan’s Otsuka, co-developed ribociclib with Novartis. Like Pfizer’s Ibrance (palbociclib), ribociclib is an inhibitor of cyclin dependent kinase 4 ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant ...

Basel, October 18, 2024 – Novartis announced today that the Committee ... granting marketing authorization for Kisqali ® (ribociclib) for the adjuvant treatment of adults with hormone receptor ...